Identification and characterization of novel therapeutic targets and biomarkers in chronic myeloid leukemia
Chronic myeloid leukemia (CML) has long served as a paradigm for new insights into the cellular origin, pathogenesis and treatment of human cancers. ABL tyrosine kinase inhibitor (TKI) therapies have had remarkable effects on treatment of early phase CML. However, TKI monotherapies are not curative,...
| Main Author: | |
|---|---|
| Language: | English |
| Published: |
University of British Columbia
2016
|
| Online Access: | http://hdl.handle.net/2429/58470 |